š”š²šš š¦ššŗšŗš®šæš
ā¢ Lupin received tentative approval from the USFDA for its Abbreviated New Drug Application for Canagliflozin Tablets, a generic equivalent of Invokana Tablets.
ā¢ The company also received approval for its ANDA concerning Bromfenac Ophthalmic Solution, making it eligible for a 180-day exclusivity period.
ā¢ In Q2FY24, Lupin reported a 277% year-on-year rise in consolidated net profit and a growth in revenue and EBITDA.